Compass Therapeutics (NASDAQ:CMPX) Rating Lowered to Market Perform at Leerink Partners

Compass Therapeutics (NASDAQ:CMPX) was downgraded by equities research analysts at Leerink Partners from an “outperform” rating to a “market perform” rating in a report released on Friday, Marketbeat.com reports. They presently have a $4.00 target price on the stock, down from their prior target price of $5.00. Leerink Partners’ price objective suggests a potential upside of 189.86% from the company’s previous close.

CMPX has been the topic of a number of other reports. LADENBURG THALM/SH SH raised Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price target on the stock in a research note on Monday, September 16th. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Compass Therapeutics in a research report on Monday, November 11th. Finally, Wedbush reissued an “outperform” rating and issued a $8.00 target price on shares of Compass Therapeutics in a research note on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $6.75.

Compass Therapeutics Stock Down 13.2 %

Shares of Compass Therapeutics stock opened at $1.38 on Friday. The firm has a market cap of $189.87 million, a PE ratio of -3.73 and a beta of 0.92. Compass Therapeutics has a twelve month low of $0.77 and a twelve month high of $2.34. The business has a 50-day moving average price of $1.75 and a 200 day moving average price of $1.42.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.03. On average, sell-side analysts expect that Compass Therapeutics will post -0.42 EPS for the current year.

Institutional Investors Weigh In On Compass Therapeutics

A number of hedge funds have recently modified their holdings of CMPX. Rovin Capital UT ADV acquired a new position in Compass Therapeutics in the 3rd quarter valued at about $25,000. Intech Investment Management LLC acquired a new position in Compass Therapeutics in the third quarter valued at approximately $30,000. XTX Topco Ltd purchased a new position in Compass Therapeutics in the third quarter worth approximately $37,000. Cubist Systematic Strategies LLC acquired a new stake in Compass Therapeutics during the second quarter worth $41,000. Finally, Panagora Asset Management Inc. acquired a new stake in Compass Therapeutics during the second quarter worth $68,000. Hedge funds and other institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.